High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.
Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell.
One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up.
RBC Upgrade Signals Stabilizing Outlook After 2026 Selloff
Investing.com -- Pfizer shares may have found a more balanced risk-reward profile after a sharp decline this year, prompting RBC Capital Markets to upgrade the drugmaker to Sector Perform from Underperform while maintaining its $25 price target. The brokerage said the stock's roughly 11% pullback from its 2026 highs has brought valuation in line with its expectations, reducing the downside risks it had previously highlighted.
Healthcare stocks fell late Wednesday afternoon with the NYSE Healthcare Index declining 0.8% and th
Pfizer's (PFE) risk-reward profile has become more balanced following recent share weakness, with th
MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.
Pre-Market Stock Futures: Futures are trading lower after the stock market tried to take a cue from Monday’s action, and things didn’t work out quite as well on Tuesday. Once again, the market gapped open higher as the “Buy the dip” legions came in to ride what they thought would be another wave higher, only ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: BILL Holdings, Cava Group, Entergy, GlobalFoundries, Hess Midstream, Nike, Pfizer, SharkNinja, STMicroelectronics, and More
By Chris Prentice and Maggie Fick NEW YORK/LONDON, June 10 (Reuters) - Eli Lilly has solidified its leading position in the booming market for obesity drugs ahead of a wave of possible new entrants to
Pfizer (NYSE:PFE) trades at $25.62, pays a 6.7% dividend yield, and just posted five straight quarterly EPS beats before stumbling in Q1. Yet the stock is up only 6.37% YTD this year. Can Pfizer shares double to $50 by 2031? What’s Holding Pfizer Back Pfizer is down 0.23% over the past month and essentially flat ... Prediction: Pfizer Stock Will Double on This Date
U.S. FDA expands approval of HYMPAVZI for pediatric hemophilia A and B patients. Label now includes children as young as six, with and without inhibitors. First subcutaneous non factor therapy approved for hemophilia B patients ages 6 to 11. Development is material for Pfizer’s (NYSE:PFE) hemophilia segment and rare disease portfolio. For Pfizer, rare diseases sit alongside vaccines, oncology, and other therapeutics as core parts of its business mix. The broader hemophilia treatment space...
Nuvalent shares soar as GSK announces a $10.6 billion buyout deal. But is it too late already to invest in NUVL stock?
Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics portfolio, a newly expanded biosimilars platform and specialty product launches. Speaking at a Gol
Earned income has a ceiling. Hours in a day, headcount budgets, layoff cycles, and corporate restructurings all cap how much a paycheck can deliver. Passive income flips that dynamic. A properly built dividend portfolio pays you on a schedule independent of whether you showed up to work or whether your employer hit its quarter. Real ... Earn $5,000+ Yearly With These 4 Dividend Stocks
AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.
Pfizer wins FDA approval to expand Hympavzi's use in additional hemophilia A and B patient groups, including children with inhibitors.
With COVID’s windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity pipeline.
(Bloomberg) -- GSK Plc agreed to buy Nuvalent Inc. for $10.6 billion, securing a US biotech firm developing treatments for lung cancer as part of the British pharmaceutical company’s effort to rebuild its oncology franchise.Most Read from BloombergHouse Republican Says Hegseth’s D-Day Remarks ‘Inappropriate’LA Mayor Race Flips as Socialist Beats Reality TV Star PrattTrump’s $100,000 H-1B Visa Application Fee Rejected by JudgeTrump Says He, Not Congress, Is in Charge of Kennedy Center in Reversal
New data showed ecnoglutide outperformed semaglutide in a China study of 163 patients.
Pacer US Cash Cows 100 ETF (NYSEARCA:COWZ) owns the 100 Russell 1000 names that generate the most free cash flow relative to market value. That pitch has worked. COWZ trades around $64 and is up 17% over the past year. But the engine powering the fund depends on one variable holding up across cyclical sectors, ... Watch Out, Rising Capex Could Turn Today’s Cash Cows Into Dogs
At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.
Momentum is building to bring a next-generation weight loss drug to market, which could set up these three biotechs to strike a deal with a larger pharma.
Pfizer Inc. recently presented detailed Phase 2b results for berobenatide (PF’3944), an investigational once-weekly and once-monthly GLP-1 receptor agonist, showing proof of concept for meaningful weight loss with low gastrointestinal side effects across obesity and type 2 diabetes populations. The company is now planning more than 10 Phase 3 trials for berobenatide in 2026, signaling an attempt to build a broad obesity and comorbidity franchise that could reshape Pfizer’s mix of future...
The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.
Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable.
Investing.com -- Pfizer Inc (NYSE:PFE) has unveiled detailed strategy plans and clinical data for its experimental weight-loss injection, aiming to secure a foothold in a competitive market currently dominated by rivals. The New York-based pharmaceutical giant is working to catch up to industry leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO), which have captured significant market share through their first-mover advantages. Following earlier clinical setbacks, Pfizer rev
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
